These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38595954)

  • 1. Healthcare Utilization Among Infants Covered by Medicaid and Newly Diagnosed With Respiratory Syncytial Virus.
    Suh M; Movva N; Jiang X; Reichert H; Pastula ST; Sacks NC; Frankenfeld C; Fryzek JP; Simões EAF
    Open Forum Infect Dis; 2024 Apr; 11(4):ofae174. PubMed ID: 38595954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019.
    Suh M; Movva N; Jiang X; Reichert H; Bylsma LC; Fryzek JP; Nelson CB
    J Infect Dis; 2022 Aug; 226(Suppl 2):S184-S194. PubMed ID: 35968879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
    Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
    J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
    Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
    Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality Associated With Respiratory Syncytial Virus, Bronchiolitis, and Influenza Among Infants in the United States: A Birth Cohort Study From 1999 to 2018.
    Reichert H; Suh M; Jiang X; Movva N; Bylsma LC; Fryzek JP; Nelson CB
    J Infect Dis; 2022 Aug; 226(Suppl 2):S246-S254. PubMed ID: 35968877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal site of care for administration of extended half-life respiratory syncytial virus (RSV) antibodies to infants in the United States (US).
    Nelson CB; Brady BL; Richards M; Lew CR; Via W; Greenberg M; Rizzo C
    Vaccine; 2023 Sep; 41(40):5820-5824. PubMed ID: 37586957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
    Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
    J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory Syncytial Virus During the COVID-19 Pandemic Compared to Historic Levels: A Retrospective Cohort Study of a Health System.
    Movva N; Suh M; Reichert H; Hintze B; Sendak MP; Wolf Z; Carr S; Kaminski T; White M; Fisher K; Wood CT; Fryzek JP; Nelson CB; Malcolm WF
    J Infect Dis; 2022 Aug; 226(Suppl 2):S175-S183. PubMed ID: 35968868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
    Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
    BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of respiratory syncytial virus related health care utilization in the United States.
    Tong S; Amand C; Kieffer A; Kyaw MH
    J Glob Health; 2020 Dec; 10(2):020422. PubMed ID: 33110581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee.
    Rankin DA; Haddadin Z; Lipworth L; Stahl AL; Fryzek J; Suh M; Shepard DS; Varjabedian R; Fernandez KN; Salib S; Villarreal J; Bruce M; McHenry R; Spieker AJ; Nelson CB; Halasa NB
    Ther Adv Infect Dis; 2022; 9():20499361221112171. PubMed ID: 35875809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020.
    Gantenberg JR; van Aalst R; Zimmerman N; Limone B; Chaves SS; La Via WV; Nelson CB; Rizzo C; Savitz DA; Zullo AR
    J Infect Dis; 2022 Aug; 226(Suppl 2):S164-S174. PubMed ID: 35968869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.
    Franklin JA; Anderson EJ; Wu X; Ambrose CS; Simões EA
    Open Forum Infect Dis; 2016 Sep; 3(3):ofw163. PubMed ID: 27704018
    [No Abstract]   [Full Text] [Related]  

  • 18. A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.
    Suh M; Movva N; Bylsma LC; Fryzek JP; Nelson CB
    J Infect Dis; 2022 Aug; 226(Suppl 2):S195-S212. PubMed ID: 35968876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.
    Pavilack M; Clifford RA; Gonzales T; Kong AM; Wade S; McLaurin KK
    Infect Dis Ther; 2018 Mar; 7(1):121-134. PubMed ID: 29149439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.